This list is an analysis based on recent market events. It's not an investment recommendation.
About
Quia Pharma AB (publ) engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform. The company develops drugs through its pegylation technology platform. Its product pipeline includes QPG-1030 (pegylated teduglutide) for the treatment of short bowel syndrome, and QPG-1029 under pre-clinical development for stable plasma concentration, as well as antibody-drug conjugates being developed using the company's Uni-Qleaver technology-platform. The company was formerly known as QuiaPEG Pharmaceuticals Holding AB (publ) and changed its name to Quia Pharma AB (publ). Quia Pharma AB (publ) was founded in 2004 and is headquartered in Uppsala, Sweden.
What is QuiaPEG Pharmaceuticals AB (publ) stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange QuiaPEG Pharmaceuticals AB (publ) stocks are traded under the ticker 99B.STU.
Does QuiaPEG Pharmaceuticals AB (publ) pay dividends?▼
Yes, 99B.STU dividends are paid annual. The last dividend per share was 0.58 . As of today, Dividend Yield (FWD)% is 0%.
How many employees does QuiaPEG Pharmaceuticals AB (publ) have?▼
As of October 7, 2026, the company has 2 employees.
In which sector is QuiaPEG Pharmaceuticals AB (publ) located?▼
QuiaPEG Pharmaceuticals AB (publ) operates in the Health & Wellness sector.
When did QuiaPEG Pharmaceuticals AB (publ) complete a stock split?▼
The last stock split for QuiaPEG Pharmaceuticals AB (publ) was on August 18, 2023 with a ratio of 1:1.
Where is QuiaPEG Pharmaceuticals AB (publ) headquartered?▼
QuiaPEG Pharmaceuticals AB (publ) is headquartered in Uppsala, Sweden.